Kairos Pharma (NYSEAMERICAN:KAPA) Receives “Buy” Rating from D. Boral Capital

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $9.00 price target on the stock.

Separately, Maxim Group assumed coverage on Kairos Pharma in a research note on Thursday. They set a “buy” rating and a $4.00 target price on the stock.

Kairos Pharma Stock Performance

Shares of NYSEAMERICAN KAPA opened at $0.92 on Monday. The firm has a 50 day moving average price of $1.29. Kairos Pharma has a 52-week low of $0.85 and a 52-week high of $4.00.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.